How much does one dose of Cemiplimab cost? Latest price reference

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor, a monoclonal antibody drug that targets programmed death receptor 1 (PD-1). By blocking the binding of PD-1 to its ligands, it relieves tumor suppression of the immune system and enhances the anti-tumor activity of T cells, thereby helping the body recognize and attack cancer cells. The main indications for cimepilimab include patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), as well as some eligible other malignant tumor types, such as certain patients with non-non-small cell lung cancer (NSCLC). In treatment, cimepilimab can delay tumor progression and achieve long-term remission in some patients by activating the body's immune system.

Currently, the generic drug cimepri monoclonal antibody has not yet been launched in China and has not been included in medical insurance. Therefore, domestic patients have limited access to the drug and the price information is unclear. In overseas markets, the drug is already available in the US version and the European version of the original version. The common specification is 350mg/7mL (50mg/mL). The price per box is roughly between RMB 40,000 and RMB 100,000. The specific price will fluctuate due to factors such as exchange rates, procurement channels, taxes and fees. It is worth noting that there are currently no generic drugs of cimipilimab on the market. Therefore, when patients obtain drugs overseas, they need to go through regular medical institutions or authorized pharmacies and design individualized medication plans under the guidance of professional doctors.

When using cimepilimab, patients also need to pay attention to potential immune-related adverse reactions, such as rash, abnormal liver function, changes in thyroid function, or pneumonia. Therefore, standardized medication monitoring and regular follow-up are important measures to ensure the safety and efficacy of treatment.

In short, as a PD-1 inhibitor, cimepilimab has clear indications and sustainable efficacy, but it is expensive and has not yet been launched in China. Patients should understand the medication regimen and overseas access methods under the guidance of a doctor to ensure a safe and effective treatment experience.

Reference materials:https://www.libtayohcp.com/